Skip to main content

Table 3 Adverse events observed in patients administered adjuvant chemotherapy with S-1

From: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer

Toxicity No. of patients (%)
Grade 3 or higher All
Hematological toxicity
 Neutropenia 1 (3.3) 9 (30.0)
 Leukopenia 1 (3.3) 8 (26.7)
 Anemia 0 (0.0) 5 (16.7)
 Thrombocytopenia 0 0.0 3 (10.0)
 Febrile neutropenia 0 (0.0) 1 (3.3)
Non-hematological toxicity
 Nausea 1 (3.3) 8 (26.7)
 Diarrhea 1 (3.3) 4 (13.3)
 Anorexia 1 (3.3) 12 (40.0)
 Fatigue 0 (0.0) 11 (36.7)
 Stomatitis 0 0.0 4 (13.3)
 Abdominal distension 0 0.0 1 (3.3)
 Alopecia 0 0.0 1 (3.3)
 Dry skin 0 0.0 3 (6.7)
 Dysgeusia 0 0.0 4 (13.3)
 Skin pigmentation 0 0.0 6 (20.0)